drugset / Trial / NCT04803955
Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients
Phase 2
Unknown
424 enrolled
Tianjin Chasesun Pharmaceutical Co., LTD
Southwest Hospital, China · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Phase II study of Kukoamine B Mesilate in Sepsis Patients
Timeline
- Start
- 2021-05-15
- Primary completion
- 2024-05-30
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Kukoamine B Mesilate | Unknown | 16 mg | — |